Sunrest Lifescience reports Rs 4.0132 crore operating cash
Key highlights
- Sunrest Lifescience reported Rs 4.0132 crore of consolidated operating cash for the half year ended 30 September 2026.
- Inventory used Rs 7.4901 crore of cash and reached Rs 24.556 crore at 30 September 2026.
- Trade receivables provided Rs 5.2627 crore of cash, while trade payables provided Rs 3.9626 crore.
- Cash and cash equivalents fell by Rs 51.33 lakh to Rs 2.2513 crore after Rs 3.637 crore of investing outflow.
powered by IRIS

Sunrest Lifescience Limited generated Rs 4.0132 crore of consolidated net operating cash in the half year ended 30 September 2026, despite a Rs 7.4901 crore inventory build-up. A Rs 5.2627 crore release from trade receivables and a Rs 3.9626 crore increase in trade payables offset much of the inventory cash requirement.
Know Sunrest Lifescience inside out
Results, valuation, peers and who's buying, in one view.
What produced Sunrest Lifescience's operating cash flow?
Sunrest Lifescience generated Rs 4.0132 crore of net cash from operating activities for the half year ended 30 September 2026, after Rs 1.44 lakh of taxes paid. Cash generated from operations was Rs 4.0276 crore, while profit before tax was Rs 1.2379 crore under the consolidated cash-flow statement.
The indirect cash-flow method added Rs 83.11 lakh of depreciation and Rs 75.45 lakh of interest paid to profit before tax. These adjustments, alongside other reported movements, brought operating profit before working-capital changes to Rs 3.8235 crore, compared with the stated Rs 10.5676 crore in the column headed 31 March 2025.
Working-capital movements determined the conversion of operating profit into cash. Inventories used Rs 7.4901 crore, while trade receivables provided Rs 5.2627 crore, loans and advances provided Rs 1.6219 crore, and trade payables provided Rs 3.9626 crore. Other current assets used Rs 1.3854 crore, according to the cash-flow classifications.
The prior cash-flow column records a Rs 5 lakh operating outflow, compared with the current Rs 4.0132 crore inflow. However, the consolidated cash-flow statement is titled for the period ended 30 September 2025, although its current column is headed 30 September 2026 and its comparator is headed 31 March 2025; the filing therefore does not present an explicitly like-for-like half-year comparator.
How did Sunrest Lifescience's working capital balances change?
Sunrest Lifescience's inventory rose to Rs 24.556 crore at 30 September 2026 from Rs 17.0598 crore at 31 March 2026, while trade receivables fell to Rs 26.0084 crore from Rs 32.4633 crore. The balance-sheet changes show more funds held in inventory and a lower receivables balance over the six-month period.
The Rs 6.4549 crore reduction in receivables on the balance sheet is larger than the Rs 5.2627 crore cash-flow benefit reported for trade receivables. Likewise, the Rs 7.4962 crore increase in the inventory balance is slightly above the Rs 7.4901 crore inventory cash-flow use. Sunrest Lifescience says previous-year figures were regrouped wherever required, but does not provide a reconciliation between these classifications.
Short-term loans and advances fell to Rs 7.8786 crore at 30 September 2026 from Rs 9.8734 crore at 31 March 2026, while other current assets declined to Rs 4.47 lakh from Rs 30.88 lakh. The cash-flow statement separately records Rs 13 lakh of outflow from long-term liabilities, Rs 32.24 lakh from current liabilities and Rs 31.75 lakh from provisions.
Got a follow-up? Ask IRIS
How did inventory and liabilities affect Sunrest Lifescience's funding?
Sunrest Lifescience's Rs 7.4901 crore inventory use coincided with short-term borrowings rising by Rs 1.9974 crore to Rs 7.4986 crore at 30 September 2026. Total current liabilities increased by Rs 3.3083 crore to Rs 32.7711 crore over the same period.
Trade payables due to creditors other than micro enterprises rose to Rs 23.7909 crore from Rs 20.9958 crore, a balance-sheet increase of Rs 2.7951 crore. This differs from the Rs 3.9626 crore cash-flow increase in trade payables, and the filing does not explain the difference between the reported balance-sheet movement and cash-flow classification.
Long-term borrowings declined to Rs 9.4439 crore from Rs 11.9573 crore, while other long-term liabilities declined to Rs 24 lakh from Rs 37 lakh. Shareholders' funds fell to Rs 19.9635 crore from Rs 20.4273 crore as reserves and surplus declined to Rs 15.6723 crore from Rs 16.1361 crore; minority interest rose to Rs 10.5951 crore from Rs 9.1967 crore.
Investing activities used Rs 3.637 crore, comprising Rs 2.6655 crore placed in fixed deposits and Rs 97.15 lakh spent on property, plant and equipment. Financing activities used Rs 85.95 lakh, with the statement showing Rs 51.60 lakh under borrowings received as a negative figure and Rs 37.35 lakh of interest paid.
Why did Sunrest Lifescience's cash balance fall despite operating inflow?
Sunrest Lifescience's cash and cash equivalents fell by Rs 51.33 lakh to Rs 2.2513 crore at 30 September 2026 because investing and financing outflows exceeded the Rs 4.0132 crore operating inflow. The cash-flow statement starts with Rs 2.7646 crore of cash and cash equivalents and ends with Rs 2.2513 crore.
The Rs 3.637 crore investing outflow was only Rs 37.32 lakh below the operating inflow, before the Rs 85.95 lakh financing outflow. The resulting net decrease of Rs 51.33 lakh matches the difference between the opening and closing cash balances reported in the consolidated statement.
Consolidated revenue from operations was Rs 31.8854 crore for the half year ended 30 September 2026, down from Rs 34.0105 crore for the half year ended 30 September 2025. Profit before tax declined to Rs 1.2379 crore from Rs 2.0486 crore, while profit after tax declined to Rs 99.45 lakh from Rs 1.4247 crore.
The cash-flow statement follows the indirect method under Accounting Standard 3, or AS 3, issued by the Institute of Chartered Accountants of India. Under this method, the Rs 83.11 lakh depreciation adjustment and the reported working-capital movements explain why the Rs 1.2379 crore pre-tax profit differs from the Rs 4.0132 crore operating cash inflow.
Conclusion
Sunrest Lifescience reported Rs 4.0132 crore of consolidated operating cash for the half year ended 30 September 2026 even as inventory absorbed Rs 7.4901 crore. Lower receivables, lower loans and advances, and higher trade payables provided offsetting cash, but Rs 3.637 crore of investing outflow and Rs 85.95 lakh of financing outflow reduced closing cash to Rs 2.2513 crore.
The next reported balance sheet will show whether inventory remains near Rs 24.556 crore, whether receivables remain below Rs 26.0084 crore, and how short-term borrowings progress after reaching Rs 7.4986 crore at 30 September 2026. The filing also leaves unresolved the non-like-for-like labels in the consolidated cash-flow statement's comparative column, which limits direct period comparison.


